Share-based Payment Arrangement, Expense of Viridian Therapeutics, Inc.\DE from 30 Jun 2014 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Viridian Therapeutics, Inc.\DE quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 30 Jun 2014 to 31 Dec 2025.
  • Viridian Therapeutics, Inc.\DE Share-based Payment Arrangement, Expense for the quarter ending 31 Dec 2025 was $11,989,000, a 34% increase year-over-year.
  • Viridian Therapeutics, Inc.\DE Share-based Payment Arrangement, Expense for the twelve months ending 31 Dec 2025 was $44,303,000, a 5.1% increase year-over-year.
  • Viridian Therapeutics, Inc.\DE annual Share-based Payment Arrangement, Expense for 2025 was $44,303,000, a 5.1% increase from 2024.
  • Viridian Therapeutics, Inc.\DE annual Share-based Payment Arrangement, Expense for 2024 was $42,150,000, a 37% decline from 2023.
  • Viridian Therapeutics, Inc.\DE annual Share-based Payment Arrangement, Expense for 2023 was $67,172,000, a 240% increase from 2022.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Viridian Therapeutics, Inc.\DE Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $44,303,000 $11,989,000 +$3,014,000 +34% 01 Oct 2025 31 Dec 2025 10-K 26 Feb 2026 2025 FY
Q3 2025 $41,289,000 $11,250,000 +$2,530,000 +29% 01 Jul 2025 30 Sep 2025 10-Q 05 Nov 2025 2025 Q3
Q2 2025 $38,759,000 $10,844,000 -$923,000 -7.8% 01 Apr 2025 30 Jun 2025 10-Q 06 Aug 2025 2025 Q2
Q1 2025 $39,682,000 $10,220,000 -$2,468,000 -19% 01 Jan 2025 31 Mar 2025 10-Q 06 May 2025 2025 Q1
Q4 2024 $42,150,000 $8,975,000 -$17,073,000 -66% 01 Oct 2024 31 Dec 2024 10-K 26 Feb 2026 2025 FY
Q3 2024 $59,223,000 $8,720,000 -$4,886,000 -36% 01 Jul 2024 30 Sep 2024 10-Q 05 Nov 2025 2025 Q3
Q2 2024 $64,109,000 $11,767,000 -$535,000 -4.3% 01 Apr 2024 30 Jun 2024 10-Q 06 Aug 2025 2025 Q2
Q1 2024 $64,644,000 $12,688,000 -$2,528,000 -17% 01 Jan 2024 31 Mar 2024 10-Q 06 May 2025 2025 Q1
Q4 2023 $67,172,000 $26,048,000 +$20,770,000 +394% 01 Oct 2023 31 Dec 2023 10-K 26 Feb 2026 2025 FY
Q3 2023 $46,402,000 $13,606,000 +$8,663,000 +175% 01 Jul 2023 30 Sep 2023 10-Q 12 Nov 2024 2024 Q3
Q2 2023 $37,739,000 $12,302,000 +$7,417,000 +152% 01 Apr 2023 30 Jun 2023 10-Q 08 Aug 2024 2024 Q2
Q1 2023 $30,322,000 $15,216,000 +$10,557,000 +227% 01 Jan 2023 31 Mar 2023 10-Q 08 May 2024 2024 Q1
Q4 2022 $19,765,000 $5,278,000 +$1,787,000 +51% 01 Oct 2022 31 Dec 2022 10-K 03 Mar 2025 2024 FY
Q3 2022 $17,978,000 $4,943,000 +$961,000 +24% 01 Jul 2022 30 Sep 2022 10-Q 13 Nov 2023 2023 Q3
Q2 2022 $17,017,000 $4,885,000 +$1,068,000 +28% 01 Apr 2022 30 Jun 2022 10-Q 08 Aug 2023 2023 Q2
Q1 2022 $15,949,000 $4,659,000 +$1,484,000 +47% 01 Jan 2022 31 Mar 2022 10-Q 10 May 2023 2023 Q1
Q4 2021 $14,465,000 $3,491,000 +$1,748,000 +100% 01 Oct 2021 31 Dec 2021 10-K 27 Feb 2024 2023 FY
Q3 2021 $12,717,000 $3,982,000 +$3,367,000 +547% 01 Jul 2021 30 Sep 2021 10-Q 14 Nov 2022 2022 Q3
Q2 2021 $9,350,000 $3,817,000 +$3,194,000 +513% 01 Apr 2021 30 Jun 2021 10-Q 15 Aug 2022 2022 Q2
Q1 2021 $6,156,000 $3,175,000 +$2,511,000 +378% 01 Jan 2021 31 Mar 2021 10-Q 13 May 2022 2022 Q1
Q4 2020 $3,645,000 $1,743,000 01 Oct 2020 31 Dec 2020 10-K 11 Mar 2022 2021 FY
Q3 2020 $615,000 01 Jul 2020 30 Sep 2020 10-Q 05 Nov 2021 2021 Q3
Q2 2020 $623,000 01 Apr 2020 30 Jun 2020 10-Q 12 Aug 2021 2021 Q2
Q1 2020 $664,000 -$354,000 -35% 01 Jan 2020 31 Mar 2020 10-Q 07 May 2021 2021 Q1
Q1 2019 $1,018,000 +$228,000 +29% 01 Jan 2019 31 Mar 2019 10-Q 08 May 2020 2020 Q1
Q1 2018 $2,780,000 $790,000 +$371,000 +89% 01 Jan 2018 31 Mar 2018 10-Q 09 May 2019 2019 Q1
Q4 2017 $2,409,000 $716,000 +$643,000 +881% 01 Oct 2017 31 Dec 2017 10-K 14 Mar 2019 2018 FY
Q3 2017 $1,766,000 $679,000 +$634,000 +1409% 01 Jul 2017 30 Sep 2017 10-Q 09 Nov 2017 2017 Q3
Q2 2017 $1,132,000 $595,000 +$553,000 +1317% 01 Apr 2017 30 Jun 2017 10-Q 11 Aug 2017 2017 Q2
Q1 2017 $579,000 $419,000 +$381,000 +1003% 01 Jan 2017 31 Mar 2017 10-Q 09 May 2018 2018 Q1
Q4 2016 $198,000 $73,000 -$684,000 -90% 01 Oct 2016 31 Dec 2016 10-K 15 Mar 2018 2017 FY
Q3 2016 $882,000 $45,000 -$793,000 -95% 01 Jul 2016 30 Sep 2016 10-Q 09 Nov 2017 2017 Q3
Q2 2016 $1,675,000 $42,000 -$670,000 -94% 01 Apr 2016 30 Jun 2016 10-Q 11 Aug 2017 2017 Q2
Q1 2016 $2,345,000 $38,000 -$670,000 -95% 01 Jan 2016 31 Mar 2016 10-Q 11 May 2017 2017 Q1
Q4 2015 $3,015,000 $757,000 01 Oct 2015 31 Dec 2015 10-K 24 Mar 2017 2016 FY
Q3 2015 $838,000 +$135,000 +19% 01 Jul 2015 30 Sep 2015 10-Q 26 Oct 2016 2016 Q3
Q2 2015 $712,000 -$2,163,000 -75% 01 Apr 2015 30 Jun 2015 10-Q 15 Aug 2016 2016 Q2
Q1 2015 $708,000 01 Jan 2015 31 Mar 2015 10-Q 16 May 2016 2016 Q1
Q3 2014 $703,000 01 Jul 2014 30 Sep 2014 10-Q 13 Nov 2015 2015 Q3
Q2 2014 $2,875,000 01 Apr 2014 30 Jun 2014 10-Q 14 Aug 2015 2015 Q2

Viridian Therapeutics, Inc.\DE Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $44,303,000 +$2,153,000 +5.1% 01 Jan 2025 31 Dec 2025 10-K 26 Feb 2026 2025 FY
2024 $42,150,000 -$25,022,000 -37% 01 Jan 2024 31 Dec 2024 10-K 26 Feb 2026 2025 FY
2023 $67,172,000 +$47,407,000 +240% 01 Jan 2023 31 Dec 2023 10-K 26 Feb 2026 2025 FY
2022 $19,765,000 +$5,300,000 +37% 01 Jan 2022 31 Dec 2022 10-K 03 Mar 2025 2024 FY
2021 $14,465,000 +$10,820,000 +297% 01 Jan 2021 31 Dec 2021 10-K 27 Feb 2024 2023 FY
2020 $3,645,000 -$325,000 -8.2% 01 Jan 2020 31 Dec 2020 10-K 11 Mar 2022 2021 FY
2019 $3,970,000 +$291,000 +7.9% 01 Jan 2019 31 Dec 2019 10-K 26 Mar 2021 2020 FY
2018 $3,679,000 +$1,270,000 +53% 01 Jan 2018 31 Dec 2018 10-K 13 Mar 2020 2019 FY
2017 $2,409,000 +$2,211,000 +1117% 01 Jan 2017 31 Dec 2017 10-K 14 Mar 2019 2018 FY
2016 $198,000 -$2,817,000 -93% 01 Jan 2016 31 Dec 2016 10-K 15 Mar 2018 2017 FY
2015 $3,015,000 -$1,283,000 -30% 01 Jan 2015 31 Dec 2015 10-K 24 Mar 2017 2016 FY
2014 $4,298,000 01 Jan 2014 31 Dec 2014 10-K 21 Mar 2016 2015 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.